Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $.01 per share
-
Shares outstanding
-
7.04M
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
1.26M
-
Shares change
-
-469K
-
Total reported value, excl. options
-
$1.87M
-
Value change
-
-$1.08M
-
Number of buys
-
6
-
Number of sells
-
-8
-
Price
-
$1.48
Significant Holders of Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) as of Q2 2025
22 filings reported holding TRAW - Traws Pharma, Inc. - Common Stock, par value $.01 per share as of Q2 2025.
Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.26M shares
of 7.04M outstanding shares and own 17.96% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (606K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (330K shares), Vestal Point Capital, LP (150K shares), Alyeska Investment Group, L.P. (52.6K shares), GEODE CAPITAL MANAGEMENT, LLC (35.7K shares), Ikarian Capital, LLC (28.5K shares), TWO SIGMA SECURITIES, LLC (17.2K shares), TWO SIGMA INVESTMENTS, LP (16.1K shares), VANGUARD GROUP INC (13.2K shares), and BlackRock, Inc. (9.96K shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.